How Pharmaceutical Companies Can Hire AI Engineers: Why Canada Is an Emerging Talent Hub for AI Drug Discovery

Artificial intelligence is rapidly becoming part of the core research and development infrastructure at pharma companies, especially across drug discovery, clinical development, manufacturing and other stages of the drug-development lifecycle. 

The most visible examples involve drug discovery, where machine learning can help researchers understand proteins, identify potential drug targets, design molecules and prioritize which compounds should move into laboratory testing. But AI’s role is becoming much broader, with pharmaceutical companies also applying it to patient stratification, real-world evidence and other operational and scientific workflows.

The US Food and Drug Administration says it has seen significant growth in pharmaceutical submissions containing AI components, spanning nonclinical development, clinical trials, postmarketing activities and manufacturing. For pharmaceutical and biotech companies building these capabilities, that shift is changing not just how drugs are developed, but how AI teams need to be hired, validated and integrated into regulated environments.

The recruiting implications are substantial. Pharma companies increasingly need people who can operate at the intersection of machine learning, software engineering, biology, chemistry and medicine. Those professionals are considerably harder to find than generalist software engineers because understanding the AI is only part of the job. 

For US pharmaceutical and biotech companies looking for that combination of capabilities, Canada deserves particular attention. This article looks at the AI talent pharma companies need, why Canadian AI and life-science hubs matter for recruitment and how to approach hiring more strategically as demand for specialized talent rises.

AI in Pharma Is Moving From Experimentation Into the Drug-Development Process

The idea that AI might eventually transform pharmaceuticals has been discussed for years. What is different now is the degree to which major pharmaceutical companies are building infrastructure and partnerships around it.

In January 2026, Eli Lilly and NVIDIA announced an AI co-innovation laboratory focused on medicine discovery and development. The companies plan to invest up to $1 billion over five years in talent, infrastructure and computing, bringing scientists, AI researchers and engineers together to work on drug discovery while also exploring applications in clinical development, manufacturing and related areas. Lilly had already introduced its TuneLab AI/ML drug-discovery platform, trained using proprietary pharmaceutical research data that the company says cost more than $1 billion to generate. 

Other companies are moving in the same direction. Isomorphic Labs, the Alphabet company created to apply AI to drug discovery, has established collaborations with Novartis and Eli Lilly, and in 2026 expanded its work through a multi-target research collaboration with Johnson & Johnson. 

These investments demonstrate an important shift: AI in pharma is no longer simply an IT initiative. Increasingly, it sits inside the scientific process itself.

AlphaFold Shows Why AI Talent Is Becoming So Important to Pharma

Few examples illustrate the convergence of artificial intelligence and biology better than Google DeepMind’s AlphaFold. For decades, predicting how a protein would fold into its three-dimensional structure from its amino acid sequence was one of biology’s major computational challenges. 

DeepMind’s AlphaFold demonstrated that deep learning could make remarkably accurate protein-structure predictions, changing what was possible in computational structural biology. AlphaFold has since produced structural predictions covering hundreds of millions of proteins, giving researchers new tools for understanding biological systems and identifying potential therapeutic targets. 

The next generation pushed further. AlphaFold 3, developed by Google DeepMind and Isomorphic Labs, expanded beyond individual protein structures to predict interactions involving proteins, DNA, RNA, small molecules, ions and other biological components. The underlying research was published in Nature in 2024. 

That matters for drug discovery because medicines often work through interactions among molecules. Understanding those interactions computationally can help scientists evaluate biological targets and explore potential drug designs before committing significant resources to laboratory experiments.

AlphaFold’s success also helped lead to the creation of Isomorphic Labs, which Alphabet established to apply AI more directly to drug design. The talent story is just as important.

The people building these systems are not traditional pharmaceutical researchers working separately from technology teams. Increasingly, teams include machine-learning researchers, computational biologists, chemists, software engineers and drug-discovery scientists working together.

That is the kind of hiring model pharmaceutical companies increasingly need to reproduce internally.

Where Pharma Companies Can Actually Use AI

Not every pharmaceutical company needs to develop its own AlphaFold. Most should begin with the scientific or operational problems they already face.

Several areas are particularly relevant:

• Drug target identification and molecule design. Machine learning can analyze biological, genetic and chemical datasets to help researchers identify potential targets and prioritize compounds.
  
• Protein and molecular interaction modelling. Structural AI can help scientists investigate how proteins, ligands and other molecules interact.
  
• Genomics and precision medicine. Machine-learning models can analyze genomic and other biological data to identify disease mechanisms, biomarkers and patient subgroups.
  
• Clinical development. AI can support patient selection, disease-progression modelling, analysis of real-world data and more efficient clinical-trial processes.
  
• Manufacturing and quality. AI can be used for process optimization, monitoring and predictive maintenance in pharmaceutical manufacturing.
  
• Pharmacovigilance and postmarket analysis. Natural language processing and related tools can help analyze large volumes of safety and medical information.

The FDA’s own experience reflects this breadth. AI is now appearing across drug applications involving nonclinical, clinical, postmarketing and manufacturing phases rather than being restricted to one part of development. 

That also means there is no single “pharma AI engineer. The right person depends on the problem.

The Best Pharma AI Hire May Be a Scientist Who Codes, Not a Generic AI Engineer

This distinction is critical when writing the job description. A pharmaceutical company working on molecule generation may need a machine-learning research scientist with experience in graph neural networks, generative modelling or computational chemistry.

A genomics company could instead need a computational biologist who has become highly sophisticated in machine learning. A company building AI infrastructure across multiple R&D groups may need a more conventional ML engineer who understands large-scale training, model deployment and scientific data infrastructure.

Relevant roles can include:

• Machine-learning research scientists developing biological or chemical models;
• Computational biologists applying AI to genomic, proteomic or cellular datasets;
• Bioinformatics scientists building pipelines for large biological datasets;
• Computational chemists with ML expertise working on molecular prediction and design;
• Machine-learning engineers turning research models into scalable systems;
• Data and ML infrastructure engineers supporting scientific workflows; and
• AI technical leaders coordinating scientists, engineers and R&D leadership.

A résumé containing “LLM,” “RAG” and “AI agent” may therefore be far less relevant to a pharmaceutical R&D team than a candidate who understands biological foundation models, molecular representations or genomic data. The recruiting process should begin with the scientific problem and work backward toward the required technical profile.

Pharma AI Hiring Requires a Higher Standard for Validation

Pharmaceutical AI also differs from many commercial AI applications because mistakes matter differently. An unreliable recommendation engine might show someone the wrong product. An unreliable model contributing evidence to a drug-development decision can affect scientific conclusions, regulatory submissions and ultimately patient safety. 

That makes model validation and data quality especially important. The FDA has issued guidance addressing AI used to support regulatory decision-making for drugs and biologics, with an emphasis on evaluating a model’s credibility according to its specific context of use. 

The FDA and European Medicines Agency have also developed broader Good AI Practice principles for drug development, emphasizing reliable data, clear model purpose, appropriate performance assessment and lifecycle management.

This has direct implications for hiring. Pharma companies should not only ask whether a candidate can build an impressive model. They also need people capable of thinking about validation, uncertainty, reproducibility, data provenance and model limitations.

In many organizations, that means the strongest AI team will combine technical specialists with scientists and regulatory professionals rather than operating as an isolated engineering function.

Why Canada Is Particularly Strong for Pharma and AI Talent

Canada is a compelling recruiting market precisely because its strengths in AI and life sciences overlap. A 2026 Government of Canada pharmaceutical and life sciences sector report described a biotechnology ecosystem with more than 1,000 companies, highlighting particular strengths in therapeutics, genomics and AI-driven drug discovery. It identified Toronto, Montréal and Vancouver as major research hubs. 

Each city offers a somewhat different talent pool.

Toronto Combines AI, Medicine and Computational Biology

Toronto brings together the University of Toronto, Vector Institute, major hospitals and a growing biotechnology sector.

The University of Toronto offers an Artificial Intelligence in Healthcare concentration within its Master of Science in Applied Computing, specifically aimed at applying machine learning to medicine and biomedical research. 

Toronto is also home to Deep Genomics, an AI-driven genetic medicines company founded from University of Toronto research. Its platform combines biological foundation models, machine learning, laboratory workflows and drug-development expertise.

For employers, this creates a candidate market where AI professionals may already have exposure to computational biology and drug discovery rather than approaching pharma as an entirely new domain.

Montréal Connects AI Research With Life Sciences

Montréal brings together the AI ecosystem described in the previous article with a substantial biomedical research community.

McGill University researchers work across machine learning, genomics, computational biology and drug discovery, while the Montreal Neurological Institute maintains an Early Drug Discovery Unit focused on translating biological research into therapeutic opportunities. 

Mila adds one of the world’s major machine-learning research communities to that environment.

That combination is particularly attractive for companies looking for candidates whose backgrounds cross disciplinary boundaries between computer science and biology.

Vancouver Adds Biotech and Computational Drug Discovery

Vancouver has similar overlap. The University of British Columbia supports research in AI-assisted drug discovery, computational chemistry, structural biology, genomics and pharmaceutical sciences. 

Vancouver is also home to AbCellera, whose antibody-discovery platform integrates biology, computation, engineering, automation and high-throughput experimental systems. For pharmaceutical companies, Canada therefore offers more than one isolated cluster. It offers multiple markets where AI researchers, engineers and life-science professionals are already working alongside one another.

How Pharma Companies Should Approach Their First AI Hire

For a traditional pharmaceutical or biotech company building its first meaningful AI capability, the first step should not be posting a generic “AI Engineer” position.

The better process is to define four things first:

1. What problem are we solving? 

Drug discovery, computational biology, clinical trials, manufacturing and enterprise automation require different technical backgrounds.

2. What data will the person work with? 

Molecular graphs, proteins, genomic sequences, imaging, clinical data and manufacturing sensor data each require different expertise, and many pharma AI roles require a blend of software development and data science.

3. How scientifically specialized must the candidate be? 

Some roles require deep biology or chemistry knowledge. Others can succeed with a strong engineering background working closely with domain scientists.

4. Will the model influence regulated scientific decisions? 

If so, validation, reproducibility and model credibility should be part of the technical requirements from the beginning.

Once those questions are answered, recruiting becomes far more precise. The right hires often create and test machine-learning models rather than write generic software as generalist engineers.

Instead of searching broadly for “AI talent,” a company can search for the actual intersection it needs: machine learning plus genomics, AI plus computational chemistry, computer vision plus pathology, or ML infrastructure plus pharmaceutical R&D.

Pharma’s AI Talent Strategy Should Extend Beyond Traditional Hiring Markets

The lesson from AlphaFold is not that every pharmaceutical company should try to become Google DeepMind. It is that some of the most consequential developments in modern biology are now being created by teams where computer scientists and machine-learning researchers work directly alongside scientists.

Pharma is therefore competing for talent in a much broader market than it traditionally did.

The strongest candidate might come from a biotech startup, an AI laboratory, a computational-biology PhD program, a university research group or an AI-driven drug-discovery company rather than another large pharmaceutical company. Canada expands that search considerably.

Toronto, Montréal and Vancouver each sit at the intersection of advanced AI research and established life-science ecosystems. For US pharmaceutical and biotech companies struggling to recruit professionals with both technical and scientific depth, looking north of the border can open access to an unusually relevant talent pool.

How Syndesus helps US companies recruit AI and technical professionals in Canada

Pharmaceutical employers looking for highly specialized AI and life-sciences talent don’t have to restrict the search to a handful of expensive US biotech markets. Successful AI hiring in pharma isn’t about finding someone who knows the latest AI tool, it’s about finding someone who understands enough about both the model and the molecule to help turn AI into better science. 

Syndesus helps companies identify and evaluate the right AI professionals for your company. The objective is not merely to add an AI title, but to build the internal capability required for faster, more consistent, and compliant Operations. Schedule a consultation with us today.

Frequently Asked Questions About Hiring AI Engineers in Pharma